[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628851":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":10,"centralContacts":25,"locations":35,"responsibleParty":55,"collaborators":10,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":60,"sex":66,"minAge":67,"maxAge":10,"enrollmentInfo":68,"targetDuration":10,"studyType":71,"phases":10,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":38,"whyStopped":10,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"University of California, Los Angeles","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Primary Cohort",null,"Unstably housed adults without HIV being reached for healthcare by the UCLA Health Homeless Healthcare Collaborative",[13,14],"Other: Community-based healthcare delivery","Drug: Lenacapavir",[16,20],{"type":6,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"Community-based healthcare delivery","This study evaluates the implementation strategy of community-based delivery of HIV biomedical prevention with lenacapavir.",[9],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"DRUG","Lenacapavir","Mobile, community-based delivery of lenacapavir",[9],[26,31],{"name":27,"role":28,"phone":29,"phoneExt":10,"email":30},"Risa Hoffman, MD, MPH","CONTACT","310-206-6766","rhoffman@mednet.ucla.edu",{"name":32,"role":28,"phone":33,"phoneExt":10,"email":34},"Daisy Walker, MPH","424-832-6674","DaisyWalker@mednet.ucla.edu",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"UCLA Health Homeless Healthcare Collaborative","RECRUITING","Santa Monica","California","90404","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-118.49138,34.01949,{"lat":48,"lon":47},[51],{"name":52,"role":28,"phone":53,"phoneExt":10,"email":54},"Brian Zunner-Keating, RN, PHNA-BC","310-562-1871","BZunner@mednet.ucla.edu",{"type":56,"investigatorFullName":27,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Professor of Clinical Medicine","100628851","mobile-vehicle-based-delivery-of-lenacapavir-pre-exposure-prophylaxis-in-los-angeles-county-100628851",false,"NCT07467018","Mobile Vehicle-Based Delivery of Lenacapavir Pre-Exposure Prophylaxis in Los Angeles County","Mobile Vehicle-Based Delivery of Lenacapavir Pre-Exposure Prophylaxis in Los Angeles County (MOVE-LA)","MOVE-LA","Inclusion Criteria:\n\n* Being reached for mobile health services by a UCLA HHC mobile van\n* ≥18 years of age\n* Able to provide informed consent\n* English or Spanish-speaking\n* Willing and able to comply with study procedures\n* HIV unknown or negative status and HIV negative based on rapid 4th generation Ag\u002FAb test on the day of enrollment\n* At-risk for HIV, based on clinician assessment (based on CDC guidelines; includes any individual requesting PrEP, regardless of reported risk factors for HIV)\n* Pregnant and breastfeeding women\u002Fpeople can be offered LEN with counseling about benefits and risks.\n\nExclusion Criteria:\n\n* Any clinical or psychosocial condition or prior therapy that, in the opinion of the investigator, would make the participant unsuitable for the study or unable to take LEN PrEP\n* Known hypersensitivity to the study drug, the metabolites, or formulation excipient\n* BMI \\\u003C35 kg\u002Fm2 (77 pounds)\n* On oral or other long-acting PrEP and unwilling to discontinue\n* Already taking LEN for HIV prevention\n* Known HIV diagnosis or positive 4th generation HIV Ab\u002FAg test (on day of enrollment) or subsequent lab-based confirmatory testing.","ALL","18 Years",{"count":69,"type":70},100,"ESTIMATED","OBSERVATIONAL","This project evaluates the implementation strategy of the delivery of lenacapavir pre-exposure prophylaxis (LEN PrEP) - a newly available long-acting, injectable medication for human immunodeficiency virus (HIV) prevention - via a mobile health van model for people who are unstably housed in Los Angeles County (LAC). People who are unhoused or are facing housing instability experience significant barriers to accessing HIV prevention care in traditional clinic settings. In 2022, approximately 13% of newly diagnosed HIV cases in LAC were experiencing homelessness, a 36% increase over the prior period. The study will work with the University of California, Los Angeles (UCLA) Health's Homeless Healthcare Collaborative (HHC), which operates mobile health vans staffed by clinicians, social workers, and community health workers, to bring LEN PrEP directly to community settings, such as shelters, encampments, community centers, and transitional housing facilities.\n\nThis study has three primary aims:\n\n1. Characterize uptake of LEN PrEP among unstably housed people in LAC receiving health services via HHC's mobile program.\n2. Evaluate how many study participants stay on LEN PrEP through 52 weeks.\n3. Understand costs, acceptability, and sustainability of the mobile LEN PrEP delivery model.",[74],"HIV Prevention",[76,77,78,79],"lenacapavir","community-based health delivery","HIV prevention","homelessness","2026-04-21",{"date":82,"type":83},"2026-04-23","ACTUAL",{"date":80,"type":83},{"date":86,"type":70},"2027-12-31",{"name":5,"class":6},1]